ATG Service Gene

ANTIGEN CONTAINING STRUCTURAL PROTEIN SEQUENCES OF THE CORONAVIRUS SARS-COV-2

The hybrid antigen developed by us carries the antigenic determinants (epitopes) of all structural proteins of the SARS-CoV-2 coronavirus.

Our invention formed the basis for the CoronaDerm-PS test system by the Saint-Petersburg Pasteur Institute
(Eurasian patent application, number 202190517 dated 03/11/2021).

Currently, clinical trials have been completed and the drug is being registered with the Russian Federation Ministry of Health.

The development of the hybrid antigen was a continuation of the work on the development of a DNA vaccine against COVID-19, which we have been conducting since 2020.

1. Clear and reliable demonstration of the formed cellular immune response to SARS-CoV-2;
2. No special equipment is required for the test;
3. Fast and scalable production;
4. Safety of the drug, due to:
- the infectious agent is not used in the production,
- the medicinal product does not contain fragments homologous to fragments of huymsn proteins,
- does not cause complications caused by coronavirus.

5. Specificity of action. The drug has no homology with known proteins from organisms other than coronavirus;
6. High sensitivity.

Benefits of our protein for use in test systems:

08/12/2022. Invention patent application filed (No. IN-53639/EA-NF)

Vaccine for the prevention and treatment of coronavirus infection

A vector DNA vaccine providing delivery of SARS-CoV-2 coronavirus gene fragments encoding M, S, N, E protein regions and their expression in human cells has been developed. Regions of the M, S, N, E proteins for the vaccine were selected based on their T-cell immunogenicity.

In addition to stimulating the formation of antibodies, the vaccine activates the T-cell immune response, which is the main one in the case of a viral infection. This is extremely important for the formation of stable immunity, independent of virus mutations.

The vaccine forms an immune response and prevent the penetration of the virus to the cells, but does not cause a malfunction of the body's systems, because it does not contain or encode either whole coronavirus proteins or vector constructs based on other viruses.

03.12.2021. An international application for an invention patent has been filed (PCT/RU2021/050415)

100+

researches

30+

specialists

18

years of experience

60+

awards and medals

We have synthesized over 200 genes ranging in length from 150 to 8000 bp. We have experience in gene synthesizing with a large number of repeats, high G/C composition and genes containing various regulatory elements.

We perform nucleotide sequence optimization in order to increase gene expression in a given organism, remove restriction sites, and increase the stability of the mRNA structure for free.

Peptides synthesis for research purposes in the amount of 1 mg to 10 g. At your request, additional modifications of peptidessuch as: acetylation, addition of a fluorescent tag (FITC), closing of disulfide bonds, etc could be performed. The length of the peptide that we can successfully synthesize is not limited.

Development of R&D of any complexity by project teams of research engineers, biochemists, physiologists, geneticists, biotechnologists, bioengineers and technologists.

ATG Service Gene is currently successfully developing fundamental, exploratory and applied R&D in cooperation with leading research institutes and commercial organizations.

ATG Service Gene provides services for the development of dietary supplements. Our services include, among other things, the selection of new combinations of biologically active substances, the selection of enhancers of their action, testing the effectiveness of their action in vitro and in vivo, and support for the production and registration of dietary supplements.

ATG Service Gene offers a number of modern methods for the analysis of biological samples.

• HPLC
• Endotoxins detection
• Host cell protein detection
• Other tests

The ATG Service Gene company has maintained a reliable partnership with many foreign colleagues. So we are ready to offer express delivery of foreign-made reagents.

7

Special awards for the best invention

1 place

At the Geneva Exhibition of Innovations

34

Gold medals

17

Silver medals

2

Bronze medals

12

Special cups

2018 yaer

Best Innovative Project

2

1

3

4

5

Obtaining of the p17 Recombinant Protein of Human Immunodeficiency Subtype A Virus

Al-shekhadat R.I., Dukhovlinov I.V., Kobatov A.I. and others // Biotechnology. - 2010. - No. 6. - S. 19-26.

Non-viral regenerative gene therapy for mammals damaged skin

Efremov A.M., Dukhovlinov I.V., Dizhe E.B., et al. // Tsitol. - 2010. - T. 52. - No. 5. - S. 371.

The pharmacokinetics study of the three dosage forms regenerative gene therapy drug in damaged human surface tissues of various etiologies

I.V. Dukhovlinov, R.I. Al-Shehadat, A.I. Orlov // Pharmacokinetics and pharmacodynamics. - 2013. - T. 1., No. 6. - S. 35 - 39.

Evaluation of tissue regeneration using a gene therapy preparation containing the PCIGF plasmid in an experimental model of various origins wounds

I.V. Dukhovlinov, R.I. Al-Shehadat, E.A. Fedorova and others // Bulletin of St. Petersburg University. Series 11, Medicine. - 2013. - No. 3. - P. 178 - 191.

Enhancement of Plasmid DNA Immunogenicity Expressing the Human Immunodeficiency Virus Gag Protein upon Co-transfection with a Plasmid Carrying the Defensin-2β Gene

Vorozhtsova E.V., Dukhovlinov I.V., Klimov N.A., Kozlov A.P. // Bulletin of St. Petersburg University. Series 3, Biology. - 2010. - No. 4. -S. 108-116.

Contacts

Adress

199178, St. Petersburg,
pr-kt Maly V.O., d.57, building 4,
letter Zh

Phone№

E-mail

Feedback

Contact data

199178, St. Petersburg,
pr-kt Maly V.O., d.57, building 4,
letter Zh

(с) "ATG Service Gen" LLC. All rights reserved. Full or partial copying of material from the site is prohibited.